Initial use of T3P-Y058-739 in adults with advanced solid tumors

An open-label Phase I/II study of T3P-Y058-739, a genetically modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors

Aim of the study

In this clinical trial, we are investigating an experimental treatment for patients with cancer. We are conducting this study to find out the best way to administer the treatment, what side effects it has and whether it can cause the cancer to shrink or be controlled.

Who can take part?

Patients with advanced, inoperable solid tumors for which there is no alternative therapy.